Summary take home points by Dr Highland 1. PAH and PH-ILD are associated with high mortality in patients with SARDs 2. Multimodal and early screening is recommended 3. “It takes a village” work with Pulm and Cardiology colleagues @RheumNow #ACR2025 https://t.co/Xa7TecMOIe

• https://x.com/MartinezZayasMd/status/1982810925716414923/photo/1

In the #ACR25 Great AI Debate, @RADoctor and @JYazdanyMD prepared independently, but in consecutive moments agree (in a very illustrative way): guardrails - they need to happen @RheumNow https://t.co/ccLLC3adxG

• https://x.com/drdavidliew/status/1982813971657740402/photo/1
• https://x.com/drdavidliew/status/1982813971657740402/photo/1

The CLASSIC study (n=1015, 27 countries) validated revised ASAS-SPARTAN axSpA criteria. Final model achieved 79.5% sensitivity & 90.4% specificity vs global diagnosis. MRI SIJ (active + structural) was strongest predictor. HLA-B27, CRP, IBD, uveitis also included. Abstract#0854 https://t.co/GjSHE2ihVI

• https://x.com/synovialjoints/status/1982814541667762292/photo/1

#0853 Olink proteomics in anti-Ro+ pregnancies identifies macrophage-derived IL-6 & CCL3 as serum predictors of foetal AV block These pro-inflammatory proteins predicted fAVB independent of maternal diagnosis or Ab titres, pointing to new pathogenic pathways. @RheumNow #ACR25

#1627 SLR informing the 2025 @eular_org recommendations for PMR & LVV 🔍 141 studies (30 RCTs) reviewed: new & further evidence for IL-6, JAK & B-cell-targeted therapies. Data will underpin updated management guidance. @RheumNow #ACR25

#0854 @Official_ASAS & @SPARTAN_Updates revised #axSpA criteria meet targets: Sn 79.5% / Sp 90.4%. Imaging is central (SIJ MRI + structural lesions) with focused clinical items: HLA-B27, IBP, uveitis, IBD, heel enthesitis, psoriasis, ↑CRP @RheumNow #ACR25 https://t.co/i2d12y9HcD

• https://x.com/DrMiniDey/status/1982817310122344676/photo/1

Summary of (some) drugs in the pipeline for management of PAH. Slide credits: Dr Benjamin Freed ⁦@RheumNow⁩ #ACR2025 https://t.co/qazQNk4ovR

• https://x.com/MartinezZayasMd/status/1982817190987354258/photo/1

#1614 Another SLR informing the 2025 EULAR recommendations for PMR & LVV 🧭 Fast-track clinics cut blindness & diagnostic delays; multimodal imaging pathways outperform biopsy alone. Key data shaping future referral & diagnosis guidance. @RheumNow #ACR25

What is better in #PsA post #TNFi? #RCT of #secukinumab v #ustekinumab The big 🤔? #IL17Ai vs IL12/23i 🏆 #Cosentyx ✈️✅PASI ⚜️✅ACR50 Will H2H studies change our #prescribing?🤷‍♀️ #rheums Rx #IL17i>#IL12i/23i vs #derms #ACRBest #ACR25 @RheumNow @ACRheum abst#LB06 https://t.co/RpC8ymDc7H

• https://x.com/Janetbirdope/status/1982822570379325563/photo/1

#ACR25 Abstr#1525 Find me at poster hall. Super-responders exist with rituximab, not just confined to CAR-T! Our cohort study = 23/114 (20%) had resp duration >3-yrs; 15/23 were IS-Free. Poor prognostics (Non-White, APS) & shorter #SLE duration predicted super-tesponse @RheumNow https://t.co/nJQFmiIj2n

• https://x.com/Yuz6Yusof/status/1982822156774846648/photo/1
• https://x.com/Yuz6Yusof/status/1982822156774846648/photo/1

To #cycle within or go to another drug class I #axSpA? #RCT of #TNFi-IR 👇 2nd #TNFi v #IL17i #IJDM it doesn’t matter what choice as #IL17i WAS NOT superior to TNFi cycling from 1st -2nd 👍 stay in #TNFi class = change to #IL17i #ACR25 @RheumNow abst#LB09 #ACRBest @ACRheum https://t.co/VCdL5CUYUa

• https://x.com/Janetbirdope/status/1982822671504085337/photo/1
• https://x.com/Janetbirdope/status/1982822671504085337/photo/1

The CLASSIC study validated the performance of the 2009 ASAS classification criteria Model A was chosen for the revised criteria since it achieved prespecified performance targets of SN ≥75% and SP ≥90% 🔸Pso was included 🔸⬆️CRP replaced dactylitis #ACR25 @RheumNow Abs0854 https://t.co/tK52rQyaRa

• https://x.com/RHEUMarampa/status/1982822937364238726/photo/1
• https://x.com/RHEUMarampa/status/1982822937364238726/photo/1
• https://x.com/RHEUMarampa/status/1982822937364238726/photo/1

🎥 LIVE from #ACR25 Join us daily at 5 PM CST for RheumNow’s ACR Recap Live - Your must-watch debrief of the day’s biggest breakthroughs, hot abstracts, and real-time clinical takeaways. Streaming on YouTube Live, Facebook Live, X-Live & LinkedIn Live. Save the time. Be part of https://t.co/xn4yUta9Da